title: Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension.
abstract: The ability of the dopamine-1 (D1)-like receptor to stimulate adenylyl cyclase (AC) and phospholipase C (PLC), inhibit sodium transport in the renal proximal tubule (RPT), and produce natriuresis is attenuated in several rat models of hypertension. Since the inhibitory effect of D1-like receptors on RPT sodium transport is also reduced in some patients with essential hypertension, we measured D1-like receptor coupling to AC and PLC in cultures of human RPT cells from normotensive (NT) and hypertensive (HT) subjects. Basal cAMP concentrations were the same in NT (n=6) and HT (n=4). However, the D1-like receptor agonist fenoldopam increased cAMP production to a greater extent in NT (maximum response=67+/-1%) than in HT (maximum response=17+/-5%), with a potency ratio of 105. Dopamine also increased cAMP production to a greater extent in NT (32+/-3%) than in HT (14+/-3%). The fenoldopam-mediated increase in cAMP production was blocked by SCH23390 (a D1-like receptor antagonist) and by antisense D1 oligonucleotides in both HT and NT, indicating action at the D1 receptor. The stimulatory effects of forskolin and parathyroid hormone-related protein of cAMP accumulation were not statistically different in NT and HT, indicating receptor specificity and an intact G-protein/AC pathway. The fenoldopam-stimulated PLC activity was not impaired in HT, and the primary sequence and expression of the D1 receptor were the same in NT and HT. However, D1 receptor serine phosphorylation in the basal state was greater in HT than in NT and was not responsive to fenoldopam stimulation in HT. These studies demonstrate the expression of D1 receptors in human RPT cells in culture. The uncoupling of the D1 receptor in both rats (previously described) and humans (described here) suggests that this mechanism may be involved in the pathogenesis of hypertension; the uncoupling may be due to ligand-independent phosphorylation of the D1 receptor in hypertension.
authors: University of Virginia Health Sciences Center, Charlottesville, VA, USA.
authors: H
authors: H
authors: Sanada
authors: P A
authors: PA
authors: Jose
authors: D
authors: D
authors: Hazen-Martin
authors: P Y
authors: PY
authors: Yu
authors: J
authors: J
authors: Xu
authors: D E
authors: DE
authors: Bruns
authors: J
authors: J
authors: Phipps
authors: R M
authors: RM
authors: Carey
authors: R A
authors: RA
authors: Felder
mesh_terms: D000368:Aged; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000096:biosynthesis; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D015151:Immunoblotting; D007150:Immunohistochemistry; D007687:Kidney Tubules, Proximal / Q000378:metabolism*; D008297:Male; D010766:Phosphorylation; D044168:Receptor, Parathyroid Hormone, Type 1; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D018016:Receptors, Parathyroid Hormone / Q000032:analysis; D010738:Type C Phospholipases / Q000378:metabolism; D051552:beta-Adrenergic Receptor Kinases
chemical_list: D044168:Receptor, Parathyroid Hormone, Type 1; D017447:Receptors, Dopamine D1; D018016:Receptors, Parathyroid Hormone; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D051552:beta-Adrenergic Receptor Kinases; D010738:Type C Phospholipases